Navigation Links
Novel anti-malarial drug candidate found by UT Southwestern researchers
Date:5/25/2010

DALLAS May 25, 2010 As part of a multicenter study, UT Southwestern Medical Center researchers have identified a series of chemical compounds that might serve as starting points for the identification of new classes of anti-malarial drugs.

"Malaria remains one of the most globally significant infectious diseases that we face," said Dr. Margaret Phillips, professor of pharmacology at UT Southwestern and one of the senior authors of the study, which appears in the May 20 issue of Nature. Malaria affects about 40 percent of the world's population and kills about a million people a year, she said. The parasite that causes the disease is spread by mosquito bites.

Drugs are the mainstay of malaria treatment, yet the malaria parasite is notorious for developing drug resistance, which compromises current chemotherapy.

"Novel chemical compounds with anti-malarial activity represent a potent tool in the process of developing new drugs to treat this disease," Dr. Phillips said.

The study, done in collaboration with Dr. Kiplin Guy of St. Jude Children's Research Hospital in Memphis and other researchers, started with a "library" of 309,474 chemical compounds.

The researchers used a technique called high throughput screening, which allowed them to test thousands of compounds quickly to identify those with anti-malarial action.

"In addition, publishing the full set of identified compounds will maximize the chances for the most-promising candidates to move into large-scale drug development programs," Dr. Phillips said.

The screen identified 1,152 compounds that killed the parasite. The researchers then followed up with further tests to determine the mechanism of action of the identified compounds, where possible.

Dr. Phillips and her group tested whether any of the identified compounds killed malaria parasites by inhibiting an enzyme necessary to make pyrimidine, an intermediate molecule for creating DNA. She discovered that three of the library's compounds with anti-malarial activity blocked this enzyme. Two of those had similar chemical structures to a class of known compounds that she and her colleagues have been studying for possible drug development. The third compound previously was not known to target the enzyme.

"It looked very different from anything we knew about before," she said.

Having a variety of anti-malarial drugs with different chemical structures and modes of action is important because different types of drugs are given together to slow the parasite from developing resistance, Dr. Phillips said.

In all, the researchers from the various centers found 172 compounds that are "reasonable starting points" for development of new types of drugs.

"We call the identified candidates 'hits,' but if any of them are going to become drugs, they're going to have to undergo chemical modification," Dr. Phillips said. "For instance, they may need to be altered chemically to enter the cell more easily, or to improve their pharmacology so they will be more effective in people."


'/>"/>

Contact: Aline McKenzie
aline.mckenzie@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. ASCO data highlight novel anti-cancer approach that exposes tumors to immune attack
2. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
3. Third European Novel Food Approval Received by Tahitian Noni International
4. Novel nanoparticles prevent radiation damage
5. Novel soy germ-based dietary supplement, SE5-OH containing natural S-Equol, examined for safety and influence on hormones in pre- and post-menopausal women
6. Novel Method Eyed for Normalizing Blood Sugar
7. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
8. MessageSolution First in the Market to Offer All-in-One, Integrated Cloud-Based Archiving for Email, File Systems and SharePoint at Novell BrainShare 2010
9. Novel medical home program for pediatric patients, families cuts ER visits in half
10. Novel stroke treatment passes safety stage of UCI-led clinical trial
11. Reovirus may be a novel approach to prostate cancer treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... ... a new educational seminar to focus on current legislative activity and the latest ... begin at 1 p.m. Sunday, Sept. 10, and will continue through Monday, Sept. ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, one of ... Memorial Day entertaining that are sure to satisfy your guests’ flavor cravings, while ... and cheeses featured in these refreshingly balanced recipes are packed with flavor, creating ...
(Date:5/26/2017)... , ... May 26, 2017 , ... On May 24, ... which narrowly passed the U.S. House on May 4, would result in 23 million ... under continued implementation of the 2010 Patient Protection and Affordable Care Act (ACA). ...
(Date:5/26/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the Peace Agreements being discussed by President Donald Trump and the rest of the ... to speed up peace talks in the continuous battle between Israel and Palestine. The ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... , May 10, 2017 CSSi, the global ... the clinical research industry, is proud to announce the ... The new website features both enriched content and a ... and enhances the company,s already well-established position as the ... "After many months of hard work, we ...
(Date:5/9/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... on the development of oral drug delivery systems, ... has granted Oramed a patent titled, "Methods and ... covers Oramed,s invention of an oral glucagon-like peptide-1 ... hormone that stimulates the secretion of insulin from ...
(Date:5/8/2017)... May 8, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO)., ... ("WRB"), a health care service center company based ... WRB specializes in relationship management programs for leading pharmaceutical ... WRB will join Envoy Health ... services for manufacturers, biotech firms, and other service companies. ...
Breaking Medicine Technology: